307 related articles for article (PubMed ID: 35361730)
21. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
[TBL] [Abstract][Full Text] [Related]
22. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract][Full Text] [Related]
25. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
26. Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.
Hu M; Li K; Maskey N; Xu Z; Peng C; Wang B; Li Y; Yang G
Int J Clin Exp Pathol; 2014; 7(8):4685-94. PubMed ID: 25197340
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
28. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.
Badr NM; McMurray JL; Danial I; Hayward S; Asaad NY; Abd El-Wahed MM; Abdou AG; Serag El-Dien MM; Sharma N; Horimoto Y; Sircar T; Vidya R; Hoar F; Rea D; Jones JL; Stevens A; Spooner D; Merard R; Lewis P; Hunter KJ; Berditchevski F; Shaaban AM
Pathobiology; 2023; 90(1):31-43. PubMed ID: 35705026
[TBL] [Abstract][Full Text] [Related]
30. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.
Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
J Immunol Res; 2016; 2016():4757405. PubMed ID: 27777963
[TBL] [Abstract][Full Text] [Related]
31. Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse.
Moamin MR; Allen R; Woods SL; Brown JE; Nunns H; Juncker-Jensen A; Lewis CE
Front Immunol; 2023; 14():1291643. PubMed ID: 38090569
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer.
Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D
Front Immunol; 2020; 11():609337. PubMed ID: 33569057
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies.
Liu X; Xu D; Huang C; Guo Y; Wang S; Zhu C; Xu J; Zhang Z; Shen Y; Zhao W; Zhao G
J Transl Med; 2019 Jun; 17(1):192. PubMed ID: 31174544
[TBL] [Abstract][Full Text] [Related]
34. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
[TBL] [Abstract][Full Text] [Related]
35. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
[TBL] [Abstract][Full Text] [Related]
36. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract][Full Text] [Related]
37. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
38. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
39. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
40. Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer.
Dimitrova P; Vasileva-Slaveva M; Shivarov V; Hasan I; Yordanov A
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109686
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
